Skip to content
KYMR·Nasdaq·US

Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biopharmaceutical company that develops oral medicines, with discovery and development efforts primarily directed at targets in immunology. It describes a leading position in targeted protein degradation, a small molecule therapeutic modality, and has advanced multiple programs into clinical development.

Source: SEC 10-K Feb 26, 2026

Thematic Position

KYMR

Relationship Groups

Customers1
Partners4
Licensing3
Competitors4

Relationship details are part of the Pro plan.

Ended Relationships

4 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tariff
U.S. government tariffs on foreign goods pressure Kymera's input costs
SEC 10-KFeb 26, 2026

The full regulatory passage is part of the Pro plan.

5 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

1 customer · Named major customers are part of the Pro plan.